Will Investors Now Sell Novavax (NASDAQ:NVAX) Stock Following Today’s, Citigroup Downgrades?

December 20, 2017 - By Linda Rogers

 Will Investors Now Sell Novavax (NASDAQ:NVAX) Stock Following Today’s, Citigroup Downgrades?

Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.06, from 1.08 in 2017Q1. It is negative, as 16 investors sold Novavax, Inc. shares while 30 reduced holdings. 16 funds opened positions while 31 raised stakes. 122.33 million shares or 9.46% less from 135.11 million shares in 2017Q1 were reported.

Artal Group holds 0.01% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 500,000 shares. Nationwide Fund Advsrs stated it has 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Brown Advisory stated it has 93,100 shares. Barry Investment Advsrs Ltd Liability Company invested in 0.01% or 12,000 shares. Valley Natl Advisers invested in 0% or 500 shares. Rock Springs Capital Mngmt Limited Partnership reported 820,000 shares. 500 are held by Tci Wealth Advisors. Tekla Cap Mngmt Lc reported 571,000 shares. The Massachusetts-based Panagora Asset has invested 0.01% in Novavax, Inc. (NASDAQ:NVAX). D E Shaw Com invested in 0.01% or 5.51M shares. Whittier Tru accumulated 8,500 shares or 0% of the stock. Deutsche Retail Bank Ag holds 0% or 889,132 shares in its portfolio. Gsa Cap Ptnrs Limited Liability Partnership holds 0.13% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 1.69 million shares. Natl Planning Corporation holds 0% or 12,335 shares. Blackrock holds 22.51M shares.

Since August 31, 2017, it had 0 insider purchases, and 1 insider sale for $184,870 activity.

Novavax (NASDAQ:NVAX) Receives a Downgrade

The Rating of Novavax (NASDAQ:NVAX) shares have been cut by Citigroup from a “Buy” rating to a “Neutral” rating in analysts report revealed to investors on 19 December.

Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.06, from 1.08 in 2017Q1. It is negative, as 16 investors sold Novavax, Inc. shares while 30 reduced holdings. 16 funds opened positions while 31 raised stakes. 122.33 million shares or 9.46% less from 135.11 million shares in 2017Q1 were reported.

Artal Group holds 0.01% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 500,000 shares. Nationwide Fund Advsrs stated it has 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Brown Advisory stated it has 93,100 shares. Barry Investment Advsrs Ltd Liability Company invested in 0.01% or 12,000 shares. Valley Natl Advisers invested in 0% or 500 shares. Rock Springs Capital Mngmt Limited Partnership reported 820,000 shares. 500 are held by Tci Wealth Advisors. Tekla Cap Mngmt Lc reported 571,000 shares. The Massachusetts-based Panagora Asset has invested 0.01% in Novavax, Inc. (NASDAQ:NVAX). D E Shaw Com invested in 0.01% or 5.51M shares. Whittier Tru accumulated 8,500 shares or 0% of the stock. Deutsche Retail Bank Ag holds 0% or 889,132 shares in its portfolio. Gsa Cap Ptnrs Limited Liability Partnership holds 0.13% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 1.69 million shares. Natl Planning Corporation holds 0% or 12,335 shares. Blackrock holds 22.51M shares.

Since August 31, 2017, it had 0 insider purchases, and 1 insider sale for $184,870 activity.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

Among 10 analysts covering Novavax (NASDAQ:NVAX), 2 have Buy rating, 0 Sell and 8 Hold. Therefore 20% are positive. Novavax has $17 highest and $1 lowest target. $3.07’s average target is 181.65% above currents $1.09 stock price. Novavax had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, November 14 with “Hold”. The rating was maintained by Piper Jaffray with “Hold” on Tuesday, September 19. The stock has “Hold” rating by Piper Jaffray on Monday, July 24. Piper Jaffray maintained the shares of NVAX in report on Tuesday, August 11 with “Overweight” rating. The stock has “Neutral” rating by Piperjaffray on Friday, September 16. Cantor Fitzgerald maintained Novavax, Inc. (NASDAQ:NVAX) rating on Friday, July 21. Cantor Fitzgerald has “Hold” rating and $200 target. The firm has “Neutral” rating by Citigroup given on Monday, September 19. Chardan Capital Markets initiated Novavax, Inc. (NASDAQ:NVAX) on Monday, April 4 with “Neutral” rating. The stock has “Buy” rating by Ladenburg Thalmann on Wednesday, August 9. The rating was maintained by Cantor Fitzgerald on Thursday, August 10 with “Hold”.

The stock decreased 26.85% or $0.4 during the last trading session, reaching $1.09. About 27.90M shares traded or 434.64% up from the average. Novavax, Inc. (NASDAQ:NVAX) has declined 79.61% since December 20, 2016 and is downtrending. It has underperformed by 96.31% the S&P500.

Analysts await Novavax, Inc. (NASDAQ:NVAX) to report earnings on February, 26. They expect $-0.15 earnings per share, up 28.57 % or $0.06 from last year’s $-0.21 per share. After $-0.15 actual earnings per share reported by Novavax, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $338.10 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

More important recent Novavax, Inc. (NASDAQ:NVAX) news were published by: Benzinga.com which released: “More Bad News For Novavax: A Citi Downgrade” on December 19, 2017, also Seekingalpha.com published article titled: “Novavax’s November Jump: The Start Of Something Bigger?”, Fool.com published: “Why McDermott International, Chicago Bridge & Iron, and Novavax Slumped Today” on December 19, 2017. More interesting news about Novavax, Inc. (NASDAQ:NVAX) was released by: Prnewswire.com and their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: December 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.